Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + nab-paclitaxel + gemcitabine in advanced pancreatic cancer
NCT06513455Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of irinotecan liposome injection in pancreatic cancer (PC), sponsored by Harbin Medical University. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06513455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513455.